Patients with Type 2 diabetes and high cardiovascular risk due to recent acute coronary syndromes had similar rates of cardiovascular events when treated with the anti-diabetic agent alogliptin compared to placebo according to new results.
Fuente : http://feeds.sciencedaily.com/~r/sciencedaily/~3/M...
Fuente : http://feeds.sciencedaily.com/~r/sciencedaily/~3/M...